www.checkbiotech.org ; www.raupp.info ; www.czu.cz

Medicago Inc. (TSX-V: MDG), a developer of innovative protein manufacturing
solutions using plants, announced that the Company has initiated the work to
perform an animal study with Hemagglutinin (HA), January 2007.

Hemagglutinin is an antigenic glycoprotein found on the surface of the
influenza viruses and has the potential to be used to create potent vaccines
against influenza. The objective of this study is to test the immunogenicity
of the Hemagglutinin developed by Medicago.

"Proceeding with this study will give Medicago vital information about its
innovative technique of vaccine production against influenza based on
Hemagglutinin" said Andy Sheldon, President and Chief Executive Officer of
Medicago. "The results of this study, expected in the second quarter of
2007, will provide the Company with significant data necessary to the
production of an efficient influenza vaccine. Medicago will therefore
possess another tool to implement its business plan which addresses the
increasing global vaccine demand".

To face pandemic and seasonal vaccine supply challenges, Medicago has
developed a proprietary transient expression system which produces
recombinant vaccine antigens in the cells of non-transgenic plants. This
technology offers significant advantages of efficiency, speed and cost over
the traditional egg-based and cell culture technologies. In the context of
an influenza pandemic, Medicago could be in a position to produce influenza
vaccines with unprecedented surge capacity which impacts directly on the
severity of the outbreak. This HA animal study will complete 6-months of
development from Dr Vézina's team during which Medicago's new technology has
been optimized for the production of influenza antigens.

About Medicago:
Medicago is a biotechnology company focused on the development, production
and commercialization of protein-based biopharmaceuticals using a
proprietary manufacturing system developed from its expertise in the genetic
engineering of plants. Medicago's Proficia technology offers speed,
flexibility and cost advantages that can greatly improve the accessibility
of today's emerging biopharmaceuticals for both partners and patients. The
Company has established collaboration agreements notably with Acambis PLC
(NASDAQ: ACAM, www.acambis.com) for the development of several products and
is also developing its own proprietary pipeline.

Forward looking statements
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.

[www.cnw.ca]